GET DAILY SIGNALSWhy Is HeartFlow (HTFL) Stock Up +26.8% Today?
Key Takeaways
- HeartFlow shares surged approximately 26.8% in early trading Thursday, changing hands around $39.32 versus Wednesday’s close of $31.01.
- The move was an earnings-driven rally after second-quarter results beat expectations and the company raised its full-year outlook.
- Plaque Analysis was the standout growth driver, with revenue of $7.8 million coming in about $4 million above internal expectations.
- Analysts raised price targets following the report, reinforcing bullish sentiment.
- The stock was trading within roughly 5% of its 52-week high of $41.22.
- Traders are watching Plaque adoption, second-half execution, and upcoming clinical data readouts.
Opening Summary
HeartFlow, Inc. (HTFL) is a medical technology company that provides AI-powered, non-invasive solutions for diagnosing and managing coronary artery disease. Its shares rallied sharply in early trading Thursday, rising $8.31, or about 26.8%, to $39.32, compared with a prior closing price of $31.01 on Wednesday. The move extended a strong pre-market surge and reflected an enthusiastic market reaction to second-quarter 2026 results released after Wednesday’s close, which beat revenue expectations and included raised full-year guidance.
Q2 Earnings Beat and Raised Full-Year Outlook
HeartFlow (HTFL) reported second-quarter revenue of $64.1 million, up 48% year over year and above the consensus estimate of about $56.6 million. U.S. revenue rose 51% to $59.6 million, while international and other revenue reached $4.5 million. The company’s non-GAAP net loss narrowed to $5.8 million, or $0.07 per share, from $17.6 million, or $2.79 per share, in the same period a year earlier.
Management also raised its full-year 2026 revenue guidance to a range of $246 million to $250 million, implying growth of 40% to 42%, up from a prior outlook of $228 million to $232 million. The company increased its full-year non-GAAP gross margin guidance to approximately 82% and reiterated its target of reaching cash flow profitability by mid-2028.
Plaque Momentum and Margin Expansion
A key driver of the quarter was HeartFlow’s Plaque Analysis business. Plaque revenue of $7.8 million represented about 12% of total revenue and came in roughly $4 million above the company’s expectations. Management said new account activations were ahead of plan and that coverage had reached about 78% of insured lives. The company raised its full-year Plaque revenue outlook to $29 million to $31 million and now expects approximately 1,250 activated Plaque accounts by year-end.
The core FFRCT business also contributed, with U.S. FFRCT revenue growing about 32% during the quarter. Gross margin expanded to 83.3%, up 770 basis points from 75.6% a year earlier, supported by volume leverage, AI-driven efficiencies, and a higher mix of high-margin Plaque revenue.
Analyst Price-Target Increases Reinforce the Move
The earnings-driven stock move was amplified by a wave of analyst activity. Stifel raised its price target on HTFL to $45 from $40 and maintained a Buy rating, citing strength in both the Plaque and FFRCT businesses. J.P. Morgan maintained a Buy rating with a $45 price target, while Wells Fargo maintained a Buy rating with a $39 target. The analyst response reinforced the view that HeartFlow’s accelerating revenue growth and improving margins are gaining credibility on Wall Street.
Market Context and Trading Activity
The rally appeared to be company-specific rather than driven by broad market or sector action. Shares jumped more than 20% in pre-market trading and extended those gains after the opening bell, moving from Wednesday’s close of $31.01 to around $39.32 by mid-morning Thursday. Wednesday’s regular-session volume of roughly 1.07 million shares was more than double the prior nine-session average of about 425,000 shares, indicating elevated investor interest even before the earnings announcement. The stock also traded near the upper end of its 52-week range, approaching its 52-week high of $41.22.
What Comes Next for HTFL
Investors will now focus on whether HTFL can sustain its Plaque adoption momentum and deliver on its raised revenue and margin guidance through the second half of 2026. Key catalysts include continued account activations, reimbursement developments, the DECIDE one-year outcomes expected in the fourth quarter, and broader evidence supporting expansion into the asymptomatic patient market. Risks include an ongoing competitive and regulatory environment, persistent GAAP losses, and a premium valuation that leaves the shares sensitive to any execution shortfall.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing traders to explore automated approaches matched to different market environments. Readers interested in AI-driven market analysis can visit the page to review the latest top-performing strategies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
HTFL in +7.38% Uptrend, advancing for three consecutive days on November 12, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HTFL advanced for three days, in 79 of 87 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
HTFL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 53 of 67 cases where HTFL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for HTFL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 6 similar instances where the indicator moved out of overbought territory. In 6 of the 6 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 12 of 14 cases where HTFL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HTFL as a result. In 24 of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for HTFL turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 8 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
HTFL moved below its 50-day moving average on November 13, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTFL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.289) is normal, around the industry mean (4.523). P/E Ratio (-16.610) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. HTFL's P/S Ratio (19.763) is slightly higher than the industry average of (6.105).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. HTFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement